Xarelto Lawsuits Continue Their Steady Progression As Plaintiffs Look To February Status Conference

February 10, 2016 – – BloodThinnerHelp.com reports on Xarelto lawsuits consolidated in MDL No. 2592, which continue to progress in the U.S. District Court for the Eastern District of Louisiana. The latest monthly status conference for these lawsuits was held on January 22nd of 2015, where those involved shared bellwether trial selections. In addition, according to the minute entry notes of that meeting, the Court is said to hear arguments concerning a proposed order governing interactions between the plaintiffs’ physicians and the parties, which is currently scheduled to take place on February 23rd, just after the next monthly status conference, which will be held on the same day.

Xarelto lawsuits were consolidated to form multidistrict litigation number 2592 by the U.S. Judicial Panel on Multidistrict litigation. This consolidation helps to ‘fast track’ the litigation process by helping avoid different rulings from more than one judge, as well as duplicate discovery items. In addition, it conserves resources for those involved. This consolidation was possible due to the strikingly similar claims contained in each lawsuit, and due to the fact that all lawsuits named the same defendants, (Bayer AG and Janssen Pharmaceuticals; a subdivision of the Johnson & Johnson corporation).

Court documents show a continued rise in lawsuits filed against Xarelto, with more than 2,800 federal court cases now consolidated in the MDL, and another group of over 550 cases which have been formed into a mass tort group in Philadelphia, Pennsylvania. Plaintiffs filing these cases commonly allege that blood-thinning drug Xarelto poses an increased risk to patients taking it for uncontrollable bleeding episodes, and other serious health complications. They also claim that manufacturers Janssen and Bayer neglected to properly warn the public about the drug’s risks, and instead misleadingly marketed it.

In 2011, the U.S. Food and Drug Administration approved Xarelto to treat patients healing after hip and knee replacement surgeries, as well as patients with pulmonary embolism or deep vein thrombosis. Shortly after this initial approval, the FDA expanded its approval to include treatment for patients with atrial fibrillation, who could be at increased risk for strokes.

The FDA has given Xarelto two black box warnings, which are the most severe warnings a product can get before being pulled completely from the market. Plaintiffs who have now filed suit against the drug claim that these serious warnings are just not enough. Plaintiffs are made up of those who have used Xarelto and have suffered from serious health events which they claim were caused by the drug, and family members representing loved ones who have passed away due to bleeding complications which they allege were linked to Xarelto use.

Attorney Joseph Osborne is now attempting to help ensure that everyone who has used Xarelto and suffered from adverse health effects will be given an opportunity to fully evaluate their legal options. These consumers may be entitled to significant compensation. To encourage their pursuit of justice, Attorney Osborne is offering free Xarelto consultations at this time.

To ask questions or request more information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008076